SABCS 2021

Hypothesis-generating study in the HER2-enriched…

Metformin shows no efficacy for most cancer patients

Solved and unsolved controversies of early breast…

The risk-adapted decision for or against AI has to be…

Metformin is not an anti-cancer drug

Genomic signatures of DCIS

Benefit only related to chemotherapy?!

Leading the way for other ct-DNA trials

Re-evaluation confirms old data

Critical consideration of the study data is necessary

Molecular-guided treatment is of value in combination…

Negative results with hope for translational projects

The next standard for TNBC?!

Genomisch gesteuererte Therapie sinnvoll in Kombi mit…

E’ solo effetto della chemioterapia?

Kritische Betrachtung der Studiendaten notwendig

La metformina non può essere considerata un farmaco…

"Signatures Genomiche " nel carcinoma duttale in situ

Negative Ergebnisse, aber Hoffnung für translationale…

Erneute Auswertung bestätigt alte Daten

Hypothesen-generierende Studie beim HER2-enriched…

RxPONDER: Benefit only for pre-menopausal patients?…

cTRAK TN: ctDNA monitoring not yet ready for primetime.…

MOLECULAR DIAGNOSTICS EBC: ctDNA for early detection of…

HR+ EBC: What about PALLAS/PENELOPE-B? What is the…

HER2+ EBC: Chemotherapy free regimens? Extended…

Dato-Dxd for metastatic TNBC

PFS improvement with fulvestrant in patients with…

Chekpoint inhibition in breast cancer

Exciting novel therapies for metastatic TNBC

Dato-DXd new promising ADC

Pioneering study of personalized medicine in advanced…

Reconfirming effect of T-DXd in patients with brain…

Activity of T-Dxd across all Her2-expressing breast…

Effectiveness depending on PDL1 status

Elacestrant - less than we expected

Samuraciclib - new targeted therapy for luminal breast…

Oral SERDs for early setting and adjuvant therapy

Immuntherapy for high tumor mutation burden in…

TROP2 - new target for improved chemotherapy

IO + IO without resounding success in the mBC setting

Oral SERDs are efficient, but show high progression…

Very good news for endocrine resistant metastatic…

Patients with BRCA2 don't show PFS benefit with CDK4/6i

Switching with molecular progress improves PFS

Precision oncology is beneficial in certain mBC…

TDXd is very efficient in patients with brain…

My highlights of 2021 in metastatic breast cancer

Imaging with mass cytometry can provide predictive…

Which patients will benefit from Pembro in metastatic…

Final results of the CPS score subgroup analyses show…

Best of the year: systemic therapy

Promising results for TNBC patients

3 updates - 3 new standards of care

Amazing period for patients with refractory metastatic…

Robust benefit of pembroluzimab in addition to…

Pooled analyses shows OS benefit for most subgroups

T-Dxd is also active in patients with brain metastasis

TDXd zeigt große Wirksamkeit bei Hirnmetastasen

L’imaging mass cytometry può aiutare a predire…

Werden orale SERDs die Therapie mit Fulvestrant in…

Resultados finales de los análisis de los subgrupos de…

Wirksamkeit in Abhängigkeit von PDL1-Stautus

È un grande momento per i pazienti con tumore mammario…

Best of the Year: Systemtherapie

T-Dxd aktywny również w przerzutach do mózgu

Risultati promettenti nel tumore al seno triplo…

Dato-DXd – nowy obiecujący koniugat przeciwciała i…

Buone notizie per i tumori mammari endocrino resistenti

Résultats prometteurs dans le cancer du sein triple…

Samuracyklib – nowe leczenie celowane w rakach…

Präzisionsonkologie funktioniert beim mBC

IO + IO ohne durchschlagenden Erfolg beim mBC

Umstellung bei molekularem Progress verlängert PFS

Important benefice de l’ajout du pembrolizumab à la…

HER2 Patientinnen mit BRCA2 Mutation haben PFS Nachteil…

Amélioration de la survie sans progression par le…

Mi retrospectiva del cáncer de mama metastático en 2021

Oraler Serd wirkt, aber hohe Rate an primärer Resistenz

Wegweisende Daten für die personalisierte Medizin beim…

Elacestrant – poniżej oczekiwań

Gepoolte Analyse zeigt OS Vorteil für fast alle…

Activité du T-DXd dans les metastases cérébrales

Checkpoint-Inhibition beim Mammakarzinom

MBC HR+: What is the best option after a CDK4/6i…

Integrating patients perspectives in metastatic breast…

MBC TNBC: Molecular tumor characteristics define the…

Treatment options for patients with metastatic TNBC

Therapy of brain metastasis – can T-DXd be the new SoC?

Are SERDs a future therapy for endocrine resistant…

Targeting rare mutations in breast cancer - is this the…